S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Embecta (EMBC) Stock Price, News & Analysis

$14.84
+0.09 (+0.61%)
(As of 02/23/2024 ET)
Today's Range
$14.39
$14.95
50-Day Range
$14.25
$19.33
52-Week Range
$12.72
$33.07
Volume
381,496 shs
Average Volume
431,089 shs
Market Capitalization
$854.49 million
P/E Ratio
15.62
Dividend Yield
4.04%
Price Target
$16.00

Embecta MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.50 Rating Score
Upside/​Downside
7.8% Upside
$16.00 Price Target
Short Interest
Healthy
4.21% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
2.20mentions of Embecta in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$32,500 Bought Last Quarter
Proj. Earnings Growth
3.27%
From $2.14 to $2.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.91 out of 5 stars

Medical Sector

359th out of 939 stocks

Surgical & Medical Instruments Industry

45th out of 93 stocks


EMBC stock logo

About Embecta Stock (NASDAQ:EMBC)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

EMBC Stock Price History

EMBC Stock News Headlines

Embecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Embecta Shareholders Approve Directors and Compensation Plans
Embecta Shares Fall Despite Outlook Raise, Strong 1Q
Embecta Sinks As Outlook Comes In Below Consensus
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Embecta Stock Is Tanking Today
Why Embecta Stock Is Tanking Today
Earnings Preview For Embecta
Embecta Corp's Dividend Analysis
Embecta: Q4 Earnings Insights
See More Headlines
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/15 Dividend
12/01/2023
Dividend Payable
12/15/2023
Last Earnings
2/09/2024
Today
2/23/2024
Ex-Dividend for 3/15 Dividend
2/27/2024
Dividend Payable
3/15/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+8.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$70.40 million
Pretax Margin
5.69%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$3.64 per share
Book Value
($13.78) per share

Miscellaneous

Free Float
57,418,000
Market Cap
$849.31 million
Optionable
Optionable
Beta
0.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Devdatt Kurdikar (Age 56)
    President, CEO & Director
    Comp: $2.2M
  • Mr. Jacob P. Elguicze (Age 51)
    Senior VP & CFO
    Comp: $1.05M
  • Mr. Brian R. Capone (Age 49)
    VP, Chief Accounting Officer & Corporate Controller
    Comp: $645.16k
  • Mr. Jeffrey Z. Mann (Age 52)
    Senior VP, General Counsel, Head of Business Development & Corporate Secretary
    Comp: $959.45k
  • Mr. Shaun Curtis (Age 55)
    Senior Vice President of Global Manufacturing & Supply Chain
    Comp: $915.67k
  • Ms. Colleen Riley (Age 60)
    Senior VP & Chief Technology Officer
  • Mr. Pravesh Khandelwal
    VP & Head of Investor Relations
  • Ms. Ginny Blocki
    Senior Vice President of Global Marketing & Product Management
  • Ms. Jean M. Casner (Age 66)
    Senior VP & Chief Human Resources Officer
  • Mr. Tom Blount (Age 50)
    Senior VP & President of North America














EMBC Stock Analysis - Frequently Asked Questions

Should I buy or sell Embecta stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EMBC shares.
View EMBC analyst ratings
or view top-rated stocks.

What is Embecta's stock price target for 2024?

2 equities research analysts have issued twelve-month price targets for Embecta's stock. Their EMBC share price targets range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for EMBC
or view top-rated stocks among Wall Street analysts.

How have EMBC shares performed in 2024?

Embecta's stock was trading at $18.93 at the start of the year. Since then, EMBC stock has decreased by 21.6% and is now trading at $14.84.
View the best growth stocks for 2024 here
.

Are investors shorting Embecta?

Embecta saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 2,380,000 shares, a drop of 9.2% from the January 15th total of 2,620,000 shares. Based on an average daily volume of 488,900 shares, the days-to-cover ratio is currently 4.9 days. Currently, 4.2% of the shares of the stock are short sold.
View Embecta's Short Interest
.

When is Embecta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our EMBC earnings forecast
.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) issued its quarterly earnings data on Friday, February, 9th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.15. The business had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. Embecta had a net margin of 4.93% and a negative trailing twelve-month return on equity of 18.66%. The company's revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.93 earnings per share.

How often does Embecta pay dividends? What is the dividend yield for Embecta?

Embecta declared a quarterly dividend on Friday, February 9th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.15 per share on Friday, March 15th. This represents a $0.60 annualized dividend and a dividend yield of 4.04%. The ex-dividend date of this dividend is Tuesday, February 27th.
Read our dividend analysis for EMBC
.

Is Embecta a good dividend stock?

Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 4.01%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 27.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EMBC.

What ETFs hold Embecta's stock?

ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD).Invesco S&P SmallCap Health Care ETF (PSCH).

What guidance has Embecta issued on next quarter's earnings?

Embecta issued an update on its FY 2024 earnings guidance on Friday, February, 9th. The company provided earnings per share guidance of 1.950-2.150 for the period, compared to the consensus estimate of 2.000. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Embecta's major shareholders?

Embecta's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.20%), River Road Asset Management LLC (5.75%), Yacktman Asset Management LP (4.64%), Charles Schwab Investment Management Inc. (2.24%), Balyasny Asset Management L.P. (1.49%) and Northern Trust Corp (1.16%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann.
View institutional ownership trends
.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EMBC) was last updated on 2/23/2024 by MarketBeat.com Staff